Remission of cold hemagglutinin disease induced by rituximab therapy

Cold hemagglutinin disease is a chronic hemolytic anemia that is refractory to the usual treatments for hemolytic anemia mediated by a warm-reactive antibody; it may be associated with a low-grade lymphoma. Two previous case reports point to a possible role for this agent in the treatment of cold hemagglutinin disease.1,2 Rituximab is an anti-CD20 monoclonal antibody of proven efficacy in the treatment of low-grade B-cell lymphomas.3 We report a remission of cold hemagglutinin disease in response to single-agent therapy with rituximab.

In 1987, a 39-year-old man presented with idiopathic acquired cold hemagglutinin disease. Physical examination revealed pallor and jaundice. There was no lymphadenopathy or organomegaly. He had a hemoglobin concentration of 67 g/L, a hematocrit of 20.1% and a reticulocyte count of 9.7%. His white blood cell count was 5.1 x 10^9/L with 62% neutrophils, 35% lymphocytes, 2% monocytes and 1% eosinophils. Hemagglutination was noted and improved with prewarming. The direct antiglobulin test was positive. This successful induction of remission suggests that rituximab may be an effective treatment for chronic and refractory cold hemagglutinin disease occurring in association with follicular centre cell lymphoma. The use of this agent to treat idiopathic acquired cold hemagglutinin disease requires evaluation.

Terence G. Sparling
Head
Division of Medical Oncology
Shaikh Khalifa Medical Center
Abu Dhabi, United Arab Emirates

Marina Andricevic
Clinical pharmacist
Burnaby Regional Cancer Centre
Burnaby, BC

Hilary Wass
Clinical hematologist
Victoria, BC

References

Escherichia coli infections and hemolytic-uremic syndrome

Each outbreak of verotoxigenic Escherichia coli infection renews interest in interventions to prevent the complication of hemolytic-uremic syndrome. Donald Farquhar reviewed in CMAJ a paper by Wong and colleagues that raises important concerns about risk factors for the progression to hemolytic-uremic syndrome.4 Although the authors’ concerns about antibiotic use in this context may be valid, it is critical that their conclusions not dissuade investigators from performing prospective, controlled antibiotic studies.

Wong and colleagues concluded that the association between antibiotic use and progression to hemolytic-uremic syndrome was strong, but the 95% confidence interval of the adjusted relative risk is extremely wide for antibiotic use within the first 3 days after onset of illness (1.4–737).2 If the next 1 or 2 patients with hemolytic-uremic syndrome had not received an antibiotic, the significance level might not have been maintained in the multivariate analysis. Both youth and the use of antimotility agents did not prove to be risk factors, contrary to previous findings.2,4 In addition, the authors did not find an association between antibiotic use and progression to hemolytic-uremic syndrome in a previous study with much larger numbers of patients.1 These discordances could be a function of inadequate patient numbers in the latest study.2

Perhaps more importantly, I am concerned that the approach taken to categorize antibiotic use may not have